Global Conjugated Estrogen Market 2023-2030

    In Stock

    Coming Soon.




    Conjugated oestrogens, also known as conjugated equine oestrogens, are an oestrogen drug used in menopausal hormone therapy as well as for a number of other reasons. It is marketed under the trade name Premarin among others.


    A medication called conjugated oestrogens is made up of several oestrogen hormones. It is used to treat mild to severe hot flashes, vaginal changes, and other signs of menopause or low oestrogen levels (hypoestrogenism). The risk of having a disease that can result in uterine cancer may be increased by conjugated oestrogens. cancer. 




    Infographic: Conjugated Estrogen Market, Conjugated Estrogen Market Size, Conjugated Estrogen Market Trends, Conjugated Estrogen Market Forecast, Conjugated Estrogen Market Risks, Conjugated Estrogen Market Report, Conjugated Estrogen Market Share


    The Global Conjugated Estrogen Market accounted for $XX Billion in 2022 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2023 to 2030.



    Conjugated oestrogens are a mix of oestrogens that are used in postmenopausal osteoporosis treatment as well as in the treatment of various cancers and in oestrogen replacement therapy for menopause and hypoestrogenism. treatment for moderate to severe menopausal vasomotor symptoms.


    treatment for mild to moderate vulvar and vaginal atrophy brought on by menopause.Therapy for hypoestrogenism brought on by castration, hypogonadism, or primary ovarian failure.breast cancer palliative care for carefully chosen patients with metastatic disease.palliative care for prostate cancer caused by androgen dependence.postmenopausal osteoporosis prevention treatment.


    The conjugated oestrogens function similarly to the physiological oestrogen in that they bind agonistically to the oestrogen receptors alpha and beta. The number and ratio of oestrogen receptors varies depending on the tissue, and as a result, conjugated oestrogens have a very wide range of activity.


    In order to inhibit the production of gonadotropin-releasing hormone, follicle-stimulating hormone, and luteinizing hormone, the activity produced by conjugated oestrogens is driven by an increase in the synthesis of DNA, RNA, and different proteins in sensitive tissues.


    Many distinct metabolic pathways are used to process the conjugated oestrogens. The cytochrome isoenzyme CYP3A4. drives one of the metabolic routes for conjugated oestrogens.


    The conjugated oestrogens, on the other hand, can also be broken down by a dynamic balance of metabolic interconversion and sulphate conjugation. 17-beta-estradiol is converted to estrone and then to estriol, which in turn drives some of the main metabolic processes of the conjugated oestrogens.


    The blood acts as a circulating reservoir for the production of new oestrogens by retaining some of the supplied conjugated oestrogens as sulphate conjugates.



    • Symbiotec Pharma.
    • Flavine
    • Shaoxing Hantai Pharma
    • Trade India
    • Trumac Healthcare



    1. How many Conjugated Estrogen are manufactured per annum globally? Who are the sub-component suppliers in different regions?
    2. Cost breakup of a Global Conjugated Estrogen and key vendor selection criteria
    3. Where is the Conjugated Estrogen manufactured? What is the average margin per unit?
    4. Market share of Global Conjugated Estrogen market manufacturers and their upcoming products
    5. Cost advantage for OEMs who manufacture Global Conjugated Estrogen in-house
    6. key predictions for next 5 years in Global Conjugated Estrogen market
    7. Average B-2-B Conjugated Estrogen market price in all segments
    8. Latest trends in Conjugated Estrogen market, by every market segment
    9. The market size (both volume and value) of the Conjugated Estrogen market in 2023-2030 and every year in between?
    10. Production breakup of Conjugated Estrogen market, by suppliers and their OEM relationship


    Sl no Topic
    1 Market Segmentation
    2 Scope of the report
    3 Abbreviations
    4 Research Methodology
    5 Executive Summary
    6 Introduction
    7 Insights from Industry stakeholders
    8 Cost breakdown of Product by sub-components and average profit margin
    9 Disruptive innovation in the Industry
    10 Technology trends in the Industry
    11 Consumer trends in the industry
    12 Recent Production Milestones
    13 Component Manufacturing in US, EU and China
    14 COVID-19 impact on overall market
    15 COVID-19 impact on Production of components
    16 COVID-19 impact on Point of sale
    17 Market Segmentation, Dynamics and Forecast by Geography, 2023-2030
    18 Market Segmentation, Dynamics and Forecast by Product Type, 2023-2030
    19 Market Segmentation, Dynamics and Forecast by Application, 2023-2030
    20 Market Segmentation, Dynamics and Forecast by End use, 2023-2030
    21 Product installation rate by OEM, 2023
    22 Incline/Decline in Average B-2-B selling price in past 5 years
    23 Competition from substitute products
    24 Gross margin and average profitability of suppliers
    25 New product development in past 12 months
    26 M&A in past 12 months
    27 Growth strategy of leading players
    28 Market share of vendors, 2023
    29 Company Profiles
    30 Unmet needs and opportunity for new suppliers
    31 Conclusion
    32 Appendix
      Your Cart
      Your cart is emptyReturn to Shop